AngioDynamics (NASDAQ:ANGO) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPS

AngioDynamics (NASDAQ:ANGO) announced its quarterly earnings data on Thursday. The medical instruments supplier reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.13, FiscalAI reports. AngioDynamics had a negative return on equity of 2.28% and a negative net margin of 9.02%.The company had revenue of $78.42 million for the quarter, compared to analyst estimates of $76.77 million.

Here are the key takeaways from AngioDynamics’ conference call:

• AngioDynamics reported Q3 revenue of $78.4M, up 8.9% YoY with MedTech up 19%, and raised FY26 net sales guidance to $313.5–$315.5M and adjusted EBITDA to $10–$12M (third consecutive upward revision).
• Auryon delivered its nineteenth consecutive quarter of double‑digit growth as increased hospital adoption and product line extensions (radial access, 1.7 mm catheters) drive volume and improved pricing dynamics.
• The combined mechanical thrombectomy portfolio (AlphaVac + AngioVac) grew ~18% YoY, with AlphaVac +47% YoY and +24% sequential, and the company has enrolled first patients in the pivotal APEX‑Return trial targeting approval in Q1 2027.
• NanoKnife revenue rose 21% (capital +24.9%, probes +20%), supported by the Jan 1 implementation of a CPT Category I code and expanded European indications that should boost capital placements and probe utilization.
• Gross margin fell 110 bps to 52.9% due to tariffs, inflation, and a manufacturing transition; tariffs were $1.3M in Q3 and are expected to be $4–$6M for FY26, and a planned $3–$5M inventory build for sterilization shutdowns could make FY26 cash flow slightly negative despite expected strong Q4 cash generation.

AngioDynamics Trading Down 2.4%

ANGO stock traded down $0.29 during trading on Thursday, reaching $11.65. 382,041 shares of the stock were exchanged, compared to its average volume of 552,603. The firm has a market capitalization of $480.34 million, a price-to-earnings ratio of -17.39 and a beta of 0.43. The business has a 50 day moving average price of $10.86 and a 200-day moving average price of $11.55. AngioDynamics has a 1 year low of $8.36 and a 1 year high of $13.99.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ANGO shares. Wall Street Zen downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, January 21st. Finally, Zacks Research lowered shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $19.33.

Institutional Trading of AngioDynamics

Several institutional investors have recently made changes to their positions in ANGO. Kotler Kevin purchased a new position in AngioDynamics in the fourth quarter worth approximately $21,997,000. UBS Group AG raised its position in AngioDynamics by 83.6% in the third quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock valued at $12,315,000 after purchasing an additional 501,881 shares during the period. Millennium Management LLC lifted its stake in shares of AngioDynamics by 28.1% in the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after purchasing an additional 393,682 shares during the last quarter. Nuveen LLC grew its holdings in shares of AngioDynamics by 40.5% during the 4th quarter. Nuveen LLC now owns 1,295,072 shares of the medical instruments supplier’s stock worth $16,629,000 after purchasing an additional 373,110 shares during the period. Finally, State Street Corp grew its holdings in shares of AngioDynamics by 33.0% during the 4th quarter. State Street Corp now owns 1,272,735 shares of the medical instruments supplier’s stock worth $16,342,000 after purchasing an additional 315,844 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.